Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The molecular pharmacology of glucagon agonists in diabetes and obesity
Aaron Novikoff, Timo D. Müller
Peptides (2023) Vol. 165, pp. 171003-171003
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 6, pp. 514-526
Closed Access | Times Cited: 451
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Julio Rosenstock, Juan P. Frías, Ania M. Jastreboff, et al.
The Lancet (2023) Vol. 402, Iss. 10401, pp. 529-544
Closed Access | Times Cited: 205
Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence
Muhammad Naeem, Laiba Imran, Umm E. Salma Shabbar Banatwala
Health Science Reports (2024) Vol. 7, Iss. 2
Open Access | Times Cited: 24
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Alaa Abdrabou Abouelmagd, Amro Mamdouh Abdelrehim, Mohamed Nabih Bashir, et al.
Baylor University Medical Center Proceedings (2025), pp. 1-13
Closed Access | Times Cited: 1
Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence
Emma Rose McGlone, Steve Bloom, Tricia Tan
Journal of Endocrinology (2024) Vol. 261, Iss. 3
Open Access | Times Cited: 7
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
Jonathan Brix Winther, Jens J. Holst
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 5
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Wael R. Sidrak, Sanjay Kalra, Atul Kalhan
Indian Journal of Endocrinology and Metabolism (2024) Vol. 28, Iss. 5, pp. 445-460
Open Access | Times Cited: 4
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis
Georgiana-Diana Cazac, C.M. Lǎcǎtusu, Elena-Daniela Grigorescu, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1042-1042
Open Access
GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation
Maedeh Movahednasab, Hassan Dianat‐Moghadam, Sana Khodadad, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists
Naim Alkhouri, Michael Charlton, Meagan Gray, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
Emma Rose McGlone, Tricia Tan
Peptides (2024) Vol. 176, pp. 171219-171219
Open Access | Times Cited: 2
Paradigm Shift in the Management of Metabolic Diseases—Next-Generation Incretin Therapy
Bo Åhrén
Endocrinology (2023) Vol. 164, Iss. 12
Closed Access | Times Cited: 5
Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus
Arvee Prajapati, Dhwani Rana, Shagun Rangra, et al.
International Journal of Peptide Research and Therapeutics (2024) Vol. 30, Iss. 2
Closed Access | Times Cited: 1
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity
Robert H. Gaffey, Afua K. Takyi, Alpana P. Shukla
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 8, pp. 757-773
Closed Access | Times Cited: 1
Peptide GLP-1 receptor agonists: From injection to oral delivery strategies
Zhiqiang Ke, Qianqian Ma, Xiaonan Ye, et al.
Biochemical Pharmacology (2024) Vol. 229, pp. 116471-116471
Closed Access | Times Cited: 1
Effects of Once-Weekly Subcutaneous Retatrutide on Weight and Metabolic Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Eric Pasqualotto, Rafael Oliva Morgado Ferreira, Matheus Pedrotti Chavez, et al.
Metabolism Open (2024) Vol. 24, pp. 100321-100321
Open Access | Times Cited: 1
Innovative Glucagon-Based Therapies for Obesity
Kibret Enyew Belay, Rebil Heiru Jemal, Aloys Tuyizere
Journal of the Endocrine Society (2024) Vol. 8, Iss. 12
Open Access | Times Cited: 1
Recent achievements and future directions of anti-obesity medications
Gerald Grandl, Aaron Novikoff, Xue Liu, et al.
The Lancet Regional Health - Europe (2024) Vol. 47, pp. 101100-101100
Open Access | Times Cited: 1
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
C. Allard, Daniela Cota, Carmelo Quarta
Drugs (2023) Vol. 84, Iss. 2, pp. 127-148
Closed Access | Times Cited: 3
Screening of the Key Genes and Signaling Pathways for Schizophrenia Using Bioinformatics and Next Generation Sequencing Data Analysis
Basavaraj Vastrad, Chanabasayya Vastrad
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
La strana coppia
Michelantonio De Fano, Francesca Porcellati, Carmine G. Fanelli, et al.
il Diabete (2024) Vol. 36, Iss. 1
Open Access


il Diabete (2024) Vol. 36, Iss. 1
Open Access
Mechanisms of Glucagon Receptor Agonism and GLP-1/Glucagon/GIP Receptor Triple Agonism for Treatment of Diabetes and Obesity
Se Hee Min
Journal of Korean Diabetes (2024) Vol. 25, Iss. 2, pp. 82-88
Open Access
Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon
Naif H. Ali, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Cellular and Molecular Neurobiology (2024) Vol. 44, Iss. 1
Open Access
Prospects for the convergence of polyphenols with pharmaceutical drugs in Type 2 Diabetes: challenges, risks, and strategies
Swetha Reddy Allamreddy, Meenakshi Arora, Raghu Ganugula, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100003-100003
Closed Access
Page 1 - Next Page

Scroll to top